Summary
The pharmacokinetics and plasma protein binding of nitrendipine in patients with terminal renal failure have been compared with those in subjects with normal renal function.
Kinetic parameters were calculated after a single 40 mg oral dose, an i.v. injection of 3 mg and after a 15 mg i.v. infusion of nitrendipine. Steady-state plasma levels were determined after 5 days of oral treatment with 20 mg b.d.
Pharmacokinetic parameters and steady-state plasma levels in patients with renal failure did not differ from those in subjects with normal renal function.
Nitrendipine was as highly bound to plasma proteins in patients with renal failure, as in subjects with normal renal function. The plasma protein did not differ between the two.
The dosage of nitrendipine need not be modified for kinetic reasons in patients with renal failure.
Similar content being viewed by others
References
Raemsch KD, Sommer J (1984) Pharmacokinetics and metabolism of nitrendipine. In: Scriabine A, Vanov S, Deck K (eds) Nitrendipine. Urban & Schwarzenberg, Baltimore, pp 409–421
Aronoff GR, Sloan RS (1985) Nitrendipine kinetics in normal and impaired renal function. Clin Pharmacol Ther 38: 212–218
Reidenberg MM, Drayer DE (1980) Drug therapy in renal failure. Ann Rev Pharmacol Toxicol 20: 45–54
Lobo J, Jack DB, Kendall MJ (1987) Inter- and intra-subject variability of nitrendipine and the effects of food. Eur J Clin Pharmacol 32: 357–360
Kann J, Krol GJ, Raemsch KD, Burkholder DE, Levitt MJ (1984) Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers. J Cardiovasc Pharmacol 6: 968–973
Aronoff GR (1984) Pharmacokinetics of nitrendipine in patients with renal failure: Comparison to normal subjects. J Cardiovasc Pharmacol 6: 974–976
Rahn KH (1986) Pharmacokinetic und Dosierung von Calcium-Antagonisten bei Niereninsuffizienz. In: Distler A (ed) Calcium-Antagonisten in der Hochdrucktherapie. Schattauer, Stuttgart New York, 45–47
Mikus G, Eichelbaum M (1987) Pharmacokinetics, bioavailability, metabolism and haemodynamic effects of the calcium channel antagonist nitrendipine. J Cardiovasc Pharmacol 9: 140–141
Eichelbaum M, Fischer C, Heuer B Mikus G (1986) Pharmakokinetic und Metabolismus von Nitrendipin. In: Distler A (ed) Calcium-Antagonisten in der Hochdrucktherapie. Schattauer, Stuttgart New York, 35–43
Raemsch KD, Graefe KH, Scherling D; Sommer J, Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine. Am J Nephrol 6: 73–80
Kendall MJ, Lobo J, Jack DB, Main A (1987) The influence of age on the pharmacokinetics of nitrendipine. J Cardiovasc Pharmacol 9: 96–100
Baumelou A, Bentchikou A, Vray M, Jourdan I, Eugene M (1987) Nitrendipine in patients with renal disease. J Cardiovasc Pharmacol 9: 174–177
Hansson L, Andrén L, Oroe L, Rijman T (1983) Pharmacokinetic and pharmacodynamic parameters in patients treated with nitrendipine. Hypertension 5: 25–28
Dal Canton A, Esposito C, Sabbatini M, Altomonte M, Romano G, Veniero P, Uccello F, Andreucci VE (1986) Effects of nitrendipine in patients with chronic renal failure. Am J Nephrol 6: 162–164
Wandel E, Weber M, Zschiedrich H, Marx M, Koehler H (1987) Single dose effect of nitrendipine on blood pressure of haemodialysis patients with hypertension. J Cardiovasc Pharmacol 9: 295–299
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
v. Bortel, L., Böhm, R., Mooy, J. et al. Pharmacokinetics of nitrendipine in terminal renal failure. Eur J Clin Pharmacol 36, 467–471 (1989). https://doi.org/10.1007/BF00558071
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558071